SCHEMBL2593056

SCHEMBL2593056

CCCOC(=O)COc1c(-c2cccc3c2CCC3=O)ccc(OC)c1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.49
HPGD P15428 4/20 0.49
KDM4E B2RXH2 4/20 0.49
GAA P10253 1/20 0.41
HDAC4 P56524 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HSD17B10 Q99714 4/20 0.37
CASP1 P29466 1/20 0.37
CASP7 P55210 1/20 0.37
BAP1 Q92560 1/20 0.37
POLB P06746 1/20 0.35
APEX1 P27695 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
MAPT P10636 2/20 0.35
PDE4D Q08499 1/20 0.35
TSHR P16473 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
S1PR1 P21453 1/20 0.35
KMT2A Q03164 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14737245 0.94 ALDH1A1 (0.47) ALDH1A1HPGDKDM4EGAAHDAC4
SCHEMBL2591552 0.94 ALDH1A1 (0.44) ALDH1A1HPGDKDM4EGAAHSD17B10
SCHEMBL2584438 0.92 ALDH1A1 (0.51) ALDH1A1HPGDKDM4EGAAHDAC4
SCHEMBL14737375 0.88 ALDH1A1 (0.43) ALDH1A1HPGDKDM4EGAAHSD17B10
SCHEMBL2590015 0.88 ALDH1A1 (0.54) ALDH1A1HPGDKDM4EGAAHDAC4
SCHEMBL2588319 0.87 ALDH1A1 (0.48) ALDH1A1HPGDKDM4EGAAHDAC4
SCHEMBL2588193 0.87 ALDH1A1 (0.48) ALDH1A1HPGDKDM4EGAAHDAC4
SCHEMBL2593181 0.87 ALDH1A1 (0.50) ALDH1A1HPGDKDM4EGAAHDAC4
SCHEMBL2588136 0.87 ALDH1A1 (0.49) ALDH1A1HPGDKDM4EGAAHSD17B10
SCHEMBL14736996 0.86 ALDH1A1 (0.47) ALDH1A1HPGDKDM4EGAAHDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2563770-B1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2016-03-23 EP disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
EP-2563770-A1 BIARYL PHOSPHODIESTERASE INHIBITORS Leo Pharma A/S (DK) 2013-03-06 EP disclosed
WO-2011134468-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2011-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE4A ALDH1A1 824/4885HPGD 1088/4885KDM4E 1593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.